Request Expert

Expert is a Professor of Radiation Oncology, Medical Director and Director of Clinical Investigation in the Dept. of Radiation Oncology at the Employer School of Medicine. His lab research was the first to discover the relationship between clinical pneumonitis and Interleukin 1 and interleukin 6. He has authored numerous abstracts, manuscripts and book chapters and has one patent on the topic of the prevention of and therapy for radiation toxicity. Expert has several administrative and medical certificates and holds numerous professional leadership and editorial appointments for various national organizations and professional journals including as National Board Examiner for the American Board of Radiology and manuscript reviewer for the Journal of Clinical Oncology.

His research interest in the past years has focused on the translational research of the following areas: radiation normal tissue injury to lung, genotoxicity and bone marrow injury from radiation, chemoradiation interaction, radiosensitization, biomarkers of radiation injury, and radiation terror related investigations.

His laboratory research include studying the interaction between chemotherapeutic agents and ionizing radiation, radiosensitization, radiation bone marrow injury, radiosensitization using chemotherapeutic agents for human cancer and radiation genotoxcity, lung injury and circulating biomarkers. Other translational research include radioprotectors in the prevention of radiation pulmonary injury, genotoxicity and bone marrow injury from radiation in cancer patients receiving radiation and biomarkers for radiation exposure, micronucleus assays, dicentric assays and cytogenetic damage.

Expert's other research activities include clinical research on clinical protocols on large field irradiation (NIH/NSAID), the efficacy and safety of palifermin for dysphagia, chemoradiaotherapy and the consolidation of chemotherapy for locally advanced non-small cell lung cancer, Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor - rHuKGF), Taxotere (docetaxel) with concurrent radiotherapy, Cevimeline Hydrochloride at 45 mg TID, Safety and Efficacy of Benzydamine Hydrochloride 0.15% Oral Rinse, Angiogenic factor and APC DNA as markers for lung cancer, Efficacy and Safety of Cevimeline, and Low-Dose Paclitaxel Radiosensitization.


Expert has provided consultation as a grant reviewer for several universities and national science agencies regarding weapons of mass destruction, specializing in bioterror radiation use and exposure, tobacco-related disease research and radiology and oncology related topics. Expert has provided consultation as an advisory board member on several health and pharmaceutical agencies.